Intelligence / Healthtech & medtech market map / Life-science tools, instruments and laboratory services / Laboratory consumables and reagents / Discovery and screening assay reagents for biotech and pharma research teams
Discovery and screening assay reagents for biotech and pharma research teams
Single-use assay reagents, kits, plates, plasticware and general lab chemicals bought by discovery-stage biotechnology companies and the discovery/preclinical research groups of pharmaceutical companies to run screening, cell-based and biochemical assays in research workflows. Segmented by buyer organisation type (biotech and pharma R&D) and the job of generating experimental read-outs in discovery, not in regulated testing or scale-up. Excludes QC/contract testing (niche 3), scale-up purification (niche 2), clinical sample handling (niche 5) and grant-funded academic work (niche 4).
- Level
- Niche
- Segmented by
- Customer type
- Buyers
- Biotechnology companies (discovery and preclinical research) and discovery research units of pharmaceutical companies
- Buying centre
- Head of discovery biology / assay development lead, supported by lab operations manager and a procurement or category buyer; technical evaluation typically run by the assay scientist who owns the protocol, with purchasing routed through central lab procurement or e-catalogue buyers
- Start of a new discovery programme or target, which opens a fresh reagent and consumable basket
- Platform or assay technology transfer into the organisation (e.g. new screening modality adopted)
- Re-validation or method change after assay failure, contamination event or supplier discontinuation
- Annual budget reset and instrument upgrade cycles that force protocol re-specification
- Long lead times and lot-to-lot variability in critical reagents disrupting multi-week assay timelines
- Fragmented catalogue ordering across many SKUs with high freight and handling cost per order
- Supplier-specific formulations that lock the lab into one vendor's protocol and packaging
- Price increases on routine reagents with limited ability to qualify alternatives without re-qualification effort
How this was sized
$12.0B ($9.6B–$14.4B) · 2026 · Bottom-up
Parent pool for laboratory consumables and reagents, 2026: triangulated at USD 60.4B as Emergen life science tools & reagents 2026 USD 109.77B [3] x 55% assumed consumables-and-reagents share; cross-check GVR life science tools 2026 USD 202.6B [1] x 30% assumed consumables share = USD 60.8B. Parent range USD 48-72B from 45-65% and 25-35% share assumptions. Niche = parent x 20% assumed discovery-assay share = USD 12.1B, rounded to USD 12.0B; range USD 9.6-14.4B (parent range x 20%). Forecast: 12.0 x 1.07^5 = USD 16.8B by 2031, CAGR set below the 10.2% life science tools CAGR [1]/[7] because discovery consumables are more mature than instruments.
- Life Science Tools Market Size & Share Report, 2026-2033
grandviewresearch.com · 2026-09-10 - Life Science Tools & Reagents Market Size, Share & Trends | Industry Report 2035
emergenresearch.com · 2025-12-01 - Life Science Tools Market Size, Share & Trends Analysis Report By Technology, By Product & Service, By End-use, By Region, And Segment Forecasts, 2026 - 2033
giiresearch.com · 2026-06-16
Alongside it in Laboratory consumables and reagents
// Sell into Discovery and screening assay reagents for biotech and pharma research teams